Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 16, Issue 1, Pages 12-20Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2008.05.006
Keywords
Stem cell; Stroke; Bone marrow; Animal model; Cell therapy; Neurorestorative process
Categories
Ask authors/readers for more resources
Bone marrow-derived mesenchymal stein cells (MSCs) have great potential as therapeutic agents in stroke management, since they are easily accessible and call be rapidly expanded ex vivo for autologous transplantation. Increasing evidence suggests that bone marrow cells migrate throughout the brain and differentiate into neurons and glial cells. Both non-human and human MSCs have been used to treat stroke in murine models with satisfactory results. Several factors, Such as transdifferentiation, induction of neurogenesis and angiogenesis, neuroprotection, and activation of endogenous neurorestorative processes, contribute to the benefits of MSCs in the ischemic brain. Many variables, including types of MSCs. cell dose, timing of treatment, route of cell delivery and characteristics of stroke patients, influence the efficacy of MSC treatment of stroke. Although the first trials Of autologous MSC therapy in stroke patients showed promising results, the optimal approach for different clinical settings has yet to be determined. The fundamental properties of MSCs and their potential short-term and long-term toxicities also need to be determined before moving forward to use of these cells in clinical practice. (c) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available